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Antiimmunoglobulin antibodies (Ab) l have been frequently used to stimulate 
B lymphocytes (1-5) since Sell and Gell's initial observation that antiallotype Ab 
induce the proliferation of rabbit lymphocytes (6). However, certain investigators 
have been unable to induce B cell proliferation with anti-Ig Ab (7, 8) while others 
have observed that these reagents inhibit the activation of B lymphocytes (9-11). 
In  some instances,  these divergent findings could be  attributed  to  possible 
differences in lymphocyte population subset (12), maturational stage (12-14), or 
cell cycle (15-17), or to the presence of accessory cells or factors (3,  5,  16,  18). 
In contrast, other evidence suggests that the nature of the polyclonal Ab itself is 
important in determining whether or not an Ab preparation is mitogenic to the 
B cell. For example, while in some experiments inhibitory effects are mediated 
by Fc regions of certain Ig subclasses (10,  19,  20),  the fact that inhibition  has 
also been observed with Ab preparations in which the Fc region has been digested 
(21,22), suggests that the nature of the variable region influences the regulatory 
capabilities of anti-Ig reagents. 
The hypothesis underlying the present studies is that the response of the B 
lymphocyte to anti-Ig Ab is influenced by the affinity and/or epitope specificity 
of the Ab. Since polyclonal antisera consist of indeterminant mixtures of multiple 
Ab  with  distinct  affinities  and  differing  specificities,  this  hypothesis  can  be 
examined more  directly by  the use  of monoclonal  Ab  (mAb).  A  number of 
distinct anti-lgM  mAb were assayed for the ability to stimulate human B  cell 
proliferation  in  the presence and absence of T  cell supernatant.  In  addition, 
defined combinations of these mAb were tested to determine whether the signals 
delivered by combinations of mAb differ from the signals provided by individual 
mAb. 
The data obtained suggest that the ligand-binding characteristics of individual 
anti-IgM mAb influence the presence or absence of B cell proliferation and the 
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degree of the response obtained. Furthermore, the data show that combinations 
of certain  individually  nonmitogenic  mAb  induce  pronounced  B  lymphocyte 
proliferation. Moreover, at a  high ligand concentration, certain mAb mixtures, 
but not individual mAb, deliver signals for B cell activation that obviate the need 
for ancillary signals provided by T  cell supernatants. 
Materials and Methods 
Preparation of Murine Anti-Human  Hybridomas.  mAb VIIIE11,  IG6, and XG9 were 
obtained in  two fusions of the nonsecreting routine myeloma Sp 2/0 with spleen cells 
from BALB/c mice by following standard immunization and fusion protocols (23,  24). 
The same two human IgM myeloma proteins were immunogens for both fusions, mAb 
Mu 53 and P24 were generously donated by Dr. David Posnett and the late Henry Kunkel 
and were derived similarly from BALB/c mice immunized with an aggregated human u 
chain and  intact human  IgM  mAb,  respectively. Anti-IgM  mAb  5D7  was  fortuitously 
derived from spleen cells  of BALB/c mice immunized with a  partially purified human 
IgG3 myeloma protein preparation which contained some contaminating IgM. Anti-IgM 
mAb HB57  was  purchased  from the  American Type Culture Collection (J.  Kearney, 
donor). 
CBDA-4E5 anti-human  IgD mAb and PMG3A-4C6 anti-human lambda light chain 
mAb were prepared as described for anti-IgM mAb except that an IgD~ myeloma protein 
and an  IgG3~, myeloma protein, respectively, were used as immunogens.  HB45 anti- 
human kappa light chain mAb was obtained from the American Type Culture Collection 
(J. Kearney, donor). 22c6 and SG 171 mAb bind to monomorphic determinants on human 
Ia molecules (25, 26). 
Isolation and Pur~cation ofmAb.  Anti-IgM-producing hybridomas were detected in a 
solid phase, enzyme-linked immunosorbent assay  (ELISA) (horseradish peroxidase-goat 
anti-mouse  Ig  assay  kit;  New  England  Nuclear,  Boston,  MA)  and  cloned at  limiting 
dilution.  Clones were screened for binding to 9  human  IgM and  14 human  myeloma 
proteins of other Ig classes.  Selected hybrids were propagated in irradiated (350 rad), 
pristane-primed BALB/c mice. Ascitic fluid was cleared by centrifugation at 17,300 g for 
0.5 h, made 0.1% wt/vol with sodium azide and stored at 4°C. 
Anti-IgM mAb 5D7 ('y2a mouse isotype)and VIIIE11 (~,3 mouse isotype) were purified 
by affinity chromatography over protein A Sepharose (Pharmacia Fine Chemicals, Pisca- 
taway, NJ). Ascitic fluid was first precipitated with 18% wt/vol Na~SO4. The resolubilized 
precipitates were dialyzed against  0.2  M  PO4  buffer, pH  8,  before being loaded onto 
protein A Sepharose. The differential pH elution technique of Ey et al. (27) was used for 
purification; contaminating IgG 1 was removed by washing with 0.1  M citrate buffer, pH 
6, and the bound IgG2a or IgG3 hybridoma protein was eluted with 0.1  M citrate, pH 
4.5. The remaining anti-lgM mAb of IgG1 mouse isotype (HB57, Mu53, 1G6, XG9, and 
P24)  were  purified by  NazSO4  precipitation  and  ion  exchange chromatography over 
DEAE-Trisacryl (LKB Instruments,  Rockville, MD), as described by Parham et al.  (28), 
with slight modifications. Protein was loaded onto columns in 0.005 PO4 M buffer, pH 8, 
and eluted by a linear salt gradient from 0.005 to 0.1  M PO4 buffer, pH 8. All anti-IgM 
mAb eluted at a conductivity of 2.21-4.46 x  103 uS. 
The purified anti-IgM mAb were subjected to sodium dodecyl sulfate polyacrylamide 
gel  electrophoresis (29)  under  both  native  and  denaturing  conditions  in  a  5-12.5% 
acrylamide gradient gel. 20 ~tg of protein was applied in a volume of 10 #1. When stained 
with Coomassie Blue and analyzed on a densitometer, no deflections other than those 
accounted for by Igs were detected on both the nonreduced and reduced gels. Calculations 
based on densitometric tracings revealed levels of purity in all preparations of 90-95%. 
In addition, immunoelectrophoresis using goat anti-mouse serum and goat anti-mouse 
Ig as precipitating reagents showed only one precipitation line. 
CBDA-4E5 anti-human  IgD mAb (71  mouse isotype) was purified from hybridoma 
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affinity-purified goat anti-mouse Ig. Both  22c6 and SG171  mAb (~2a mouse isotypes) 
were purified from ascites by selective elution from protein A Sepharose. 
Put,cation of Human Myeloma Proteins.  Sources of monoclonal human IgM included 
serum either from patients with Waldenstr6m's macroglobulinemia or from patients with 
mixed  cryoglobulinemia  who  exhibited  a  monoclonal  IgM  spike.  IgM  proteins  were 
purified  by euglobulin  fractionation  (0.005  M  phosphate  buffer,  pH  8.6)  and  either 
Sephacryl S-300 gel filtration or protein A Sepharose affinity chromatography to remove 
contaminating IgG. In addition, some IgM preparations were subjected to Pevikon block 
or agarose gel preparative electropboresis as a preliminary purification step. IgG and IgD 
myeloma proteins were purified by either (a) absorption and selective elution from protein 
A  Sepharose,  (b)  affinity  chromatography  over  Sepharose  columns  conjugated  with 
purified murine hybridoma Abs specific for human Ig isotypes, or (c) Na2SO4 precipitation 
followed by Pevikon block electrophoresis.  IgA myeloma proteins were purified from 
serum  by a  sequence  of steps  that  involved euglobulin  precipitation  to  remove IgM, 
Na2SO4  precipitation  to enrich  for IgG and  IgA, ZnSO4  precipitation to separate IgG 
from IgA (30), and passage over protein A Sepharose to remove contaminating IgG. 
Preparation of T Cell Supernatants Containing B Cell Growth Factor Activity.  Peripheral 
blood  mononuclear cells  from  10 healthy  volunteers  were  isolated by  Ficoll-Hypaque 
density centrifugation and cultured at a concentration of 1.5  ×  106/ml in Linbro 24-well 
plates (Flow Laboratories, McLean, VA). The culture medium used to prepare factor was 
identical to that used by Sredni (31) but included  1% phytohemagglutinin (PHA). After 
incubating for 3 d at 37°C,  6% COs, and 90%  relative humidity, cells were pelleted at 
2,000  rpm for  10  rain and the supernatant was immediately frozen at -70°C.  Shortly 
before being used in experiments, all thawed aliquots were dialyzed vs. culture media at 
4°C for a minimum of 5 h, followed by sterile filtration. Preliminary experiments using 
an  affinity-purified goat  anti-human  IgM  Ab  established  that  a  30%  vol/vol dose  of 
supernatant was optimal for enhancing proliferation of human B lymphocytes. The ability 
of this supernatant to enhance B cell proliferation induced by anti-IgM mAb was shown 
to not be due to PHA, in that concentrations of PHA ranging from 0.01  to 5% did not 
mimic the effect of the T cell supernatant when added to purified B cell cultures stimulated 
with anti-lgM mAb (data not shown). 
Solid Phase Radioimmunoassays.  The  determination  of mAb  in  hybridoma culture 
supernatants was performed by solid phase radioimmunoassay (RIA) using a modification 
of techniques  reported  previously (32).  Briefly,  10  #g/ml of purified human  myeloma 
protein was incubated on wells of a polyvinylchloride (PVC) plate for 1.5 h at 37 ° C. After 
three washes, diluted hybridoma Ab was added to myeloma-coated wells and incubated 
for an additional  1.5 h. Bound mAb was detected by incubating wells with ~25,000 cpm 
of tritium (3H)-labeled, affinity-purified Ab specific for different murine Ig isotypes (32). 
Competitive Binding Radioimmunoassay.  Analogously to the direct binding RIA, each 
purified anti-IgM mAb was coated onto PVC wells (in duplicate) by incubating 50 tA of a 
l0 #g/ml solution of mAb in each well at 37°C for 90 rain. ~.5 h before the end of this 
initial coating, we prepared  1:1  mixtures composed of 1 #g/ml of a  3H-labeled human 
IgM myeloma protein (sp act, 667,000  cpm//~g) and each of the soluble anti-# mAb at 
concentrations of 0.08-50 #g/ml in fivefold dilutions. These mixtures were incubated in 
a 24-well Linbro plate at 37°C until the end of the coating incubation, at which time all 
mAb-coated wells were washed and 50 #1 of each inhibition mixture was added to wells 
coated with each anti-# mAb. After a final 3 h incubation, unbound ~H-IgM was discarded 
and plates were washed and assayed for bound 3H-IgM. Inhibition curves were plotted by 
determining the percent inhibition obtained when various concentrations of soluble anti- 
IgM mAb were used as an inhibitor. Percent inhibition values were calculated as follows: 
100  ×  [1  -  (cpm ~H-IgM bound  in  presence  of soluble  mAb inhibitor)/(cpm  3H-IgM 
bound in absence of soluble mAb inhibitor)]. 
Immunofluorescence Studies.  For  all  immunofluorescence  studies,  2  ×  105  cells  in 
phosphate-buffered saline/bovine  serum  albumin  (PBS-BSA)-azide  (assay  buffer)  were 
incubated with  100 ul  of 1,000  or  10 t~g/ml of purified mAb in a 96-well V-bottomed 
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#g/ml to ensure saturation binding of potentially low-affinity Ab (28). All tested mAb had 
previously been  ultracentrifuged  at  108,000 g  for 80  min at  4°C.  After washing four 
times  with  assay  buffer  (200  #l/wash),  tetramethylrhodamine  (TRITC)-labeled  F(ab')2 
goat anti-mouse  Ig was incubated with the cells for 20 min on ice before washing. Cells 
used for staining included: (a) Daudi, a lymphoblastoid B cell line (#,K); (b) two membrane 
IgM (mlgM)-positive chronic lymphocytic leukemias (#,K and #,~); (c) an mlgM-positive 
hairy  cell  leukemia;  and  (d)  a  B  type  chronic  lymphocytic  leukemia,  expressing  no 
detectable mlgM. For flow cytometric analyses (FACS IV; Becton Dickinson Immunocy- 
tometry Systems, Mountain View, CA), cells were analyzed by both forward narrow angle 
light scatter and fluorescence emission upon excitation at 514 nm (33).  After gating for 
viable cells on the basis of the scatter signal, the fluorescence of 10,000-15,000 cells was 
compared with that obtained when cells were stained with  100 #1 of 1,000 or  10 #g/ml 
irrelevant control Ab: MOPC-245 for 3,1  mAb,  LPC-1  for 3,2a,  and  FLOPC-21  for ~'3 
mAb. Data were collected using logarithmic amplification and plotted as the number of 
cells (ordinate) vs. log relative fluorescence intensity (abscissa).  All gain and offset param- 
eters were kept constant between different mAb. 
Isolation and Pur~cation  of B  Lymphocytes from  Human  Spleen Fragments.  Residual 
spleen fragments were obtained from both a normal spleen removed during an operative 
procedure and a spleen removed during surgery as treatment for Felty's syndrome. The 
fragments were diced and pressed through a fine stainless steel sieve. After sedimenting 
twice (1 g) to eliminate debris, the resulting single-cell suspension was layered on Ficoll- 
Hypaque and centrifuged (2,000 cpm, 20 rain) at room temperature. The interface layers 
were harvested, washed three times with PBS, and frozen in liquid nitrogen. When assayed 
for B cell,  T  cell, and  monocyte markers by visual indirect  immunofluorescence with a 
mixture  of anti-#,  anti-x,  and  anti-~  mAb,  anti-Leu-1,  and  P9  and  R17  anti-monocyte 
mAb (34), respectively, cells from both spleen sources were found to be 31-38% Ig  ÷, 35- 
40%  Leu-1 +, and <2% positive for monocytic markers. 
Immediately  before  an  experiment,  T  cells  were  removed  by  rosetting  twice  with 
neuraminidase-treated sheep red blood cells (35). The resulting spleen cell population was 
found to be >85% Ig  +, <1% Leu-1 ÷, and <1% P9  ÷ or R17 ÷. In addition, the cell surface 
activation antigen bound by mAb 4F2 (36) was expressed weakly on <1% of these T  cell- 
depleted splenocytes. 
Cell Culture Conditions  for Inducing B Cell Stimulation.  T  cell-depleted splenic lympho- 
cytes were cultured in flat-bottomed wells of a 96-well plate (Linbro) at 2 x  105 per well 
in  a  volume  of 0.2  ml.  Medium  used  for culture  consisted  of 50%  Iscove's modified 
Dulbecco's medium  and  50%  Ham's F-12  nutrient  mixture  supplemented  with  bovine 
insulin, progesterone, transferrin, 2-mercaptoethanol, trace elements, and gentamicin (37) 
and 15% fetal calf serum (Rehatuin, lot No. W60006; Armour Pharmaceutical, Phoenix, 
AZ). After 56 h of incubation, proliferation was assessed by an additional  16 h incubation 
with 1 #Ci/well [3H]thymidine (72.5 Ci/mmol; New England Nuclear, Boston, MA). Wells 
were harvested onto paper discs with a multiple automatic cell harvester, and incorporation 
of [3H]thymidine was determined by standard liquid scintillation techniques. Where raw 
data is illustrated, cpm + SEM from three identical cultures are reported; otherwise, when 
Acpm values are shown, standard error of the difference (SE diff) between test triplicate 
and control triplicate cultures are given. 
Calculation ofT Cell Supernatant Enhancement Ratio.  For each set of triplicate cultures, 
an  index  representing  the  degree  of T  cell  supernatant-dependent  proliferation  was 
calculated by computing the quotient of the Acpm obtained in cultures in the presence of 
T  cell supernatant  vs. the ~cpm obtained for cultures in its absence.  Acpm values were 
used if and only if they were >2.5 times the standard deviation of the respective control 
cultures.  Larger index values indicate that a greater degree of proliferation was obtained 
in the presence of the supernatant. 
Results 
Spec~city  of Anti-Human  IgM mAb.  Table  I  is  a  compilation  of five  experi- 
ments demonstrating  the specificity of mAb  HB57,  5D7,  VIIIE11, Mu53,  1G6, 1240  DIVERSITY  OF  HUMAN  B  CELL  RESPONSE  TO  ANTI-lgM  mAb 
TABLE  I 
Demonstration of Specificity of Anti-Human IgM Monoclonal Antibodies by Solid Phase 
Radioimmunoassay 
Murine 
mAb  isotype 
Percent cpm 3H-anti-mouse Ig bound* 
Human myeloma proteins coated onto assay wells 
Gre  Pan  Lac  Tsc  Dia  Tuc  And  Cla  Whi 
(#~)  (#K)  (3' 1  ~)  (~'2X)  (~,3K)  (74K)  (a 1 ~,)  (a2K)  (6~) 
HB57  71  31.8  32.5  2.3  t .1  0.3  1.3  0.3  1.3  0.9 
5D7  3,2a  35.0  35.0  1.0  0.5  0.4  1.0  1.0  ND  §  1.5 
VIIIEI 1  3'3  7.3*  13.6  1.9  0.9  0.2  0.9  0.5  0.7  1.0 
Mu53  3"1  18.5  27.4  0.4  0.9  0.2  0.4  0.2  0.3  0.3 
1G6  3,1  20.2  21.7  0  0.1  0.8  0  0.1  0  ND 
XG9  "yl  18.2'  42.8  2.4  0.6  0.2  0.3  0.6  1.1  0.5 
P24  3,1  14.9  18.1  0  0.6  0.4  0.4  0  0.3  ND 
Anti-K  71  3.8  29.6  4.3  0.8  33.3  28.6  0.4  23.0  1.t 
Anti-~  73  20.6  1.9  20.7  21.2  3.5  3.5  20.7  4.3  16.7 
* 3H-labeled anti-mouse isotype reagents (32) were used as probes to detect bound mAb. ~25,000 
cpm of 3H-Ab was added to each well. All data were corrected for background binding. The results 
represent a compilation of several experiments. 
Gre u heavy chain preparation was used to coat wells in this experiment. 
Not done. 
XG9, and P24 for human  IgM. The binding observed to all  non-IgM myeloma 
proteins was at least one to two orders of magnitude lower than that to the IgM 
myeloma proteins Gre or Pan. The binding of anti-light chain mAb is included 
as controls for both the presence and the relative purity of the coating myeloma 
proteins. The low levels of inappropriate specific binding observed were consist- 
ent  with  minor  contamination  of the  myeloma  preparations  by  background 
nonmyeloma Ig. Similar results obtained with seven other IgM, five other IgG, 
and two more IgA myeloma proteins,  not illustrated,  confirmed the specificity 
assignment of the mAb for human  IgM. 
Selective  Binding  of Anti-IgM  mAb  to  Epitopes  Expressed  on  lgM-bearing  B 
Cells.  The  fluorescence distribution  histograms  shown  in  Fig.  1 demonstrate 
that the anti-IgM mAb bound to determinants exposed on the surface of a B cell 
lymphoblastoid line expressing mIgM. The mAb did not bind to a B type chronic 
lymphocytic leukemia that had been previously found to lack detectable mIgM. 
Distribution histograms identical to those in Fig.  1 were observed when the mAb 
were tested on three additional leukemias that express mIgM (data not shown). 
The  histograms  illustrated  were  obtained  using  1,000  #g/ml  of mAb;  similar 
results were also obtained  when  10 t~g/ml  of each  mAb was used for staining 
(data not shown). 
Recognition  of Distinct  Epitopes  on  Human  IgM  by  Anti-IgM  mAb.  A  cross- 
inhibition  assay was performed  to  evaluate  which  anti-#  mAb  are  directed  to 
distinct determinants on human  IgM. mAb that recognize the same epitope with 
comparable affinities should each reciprocally inhibit the binding of 3H-IgM to 
the other. 
The data  from Table  II demonstrate  that:  (a) mAb  1G6 bound to a  unique RUDICH,  WINCHESTER,  AND  MONGINI 
Dau (LCL)  Ege (CLL) 
1241 
f _Y. 
5D7  ? 
VIIIE  11 
MU53 ~  . 
I  10  100  10  100 
relative  ftuorescence  intensity 
FIGURE  1.  Anti-lgM mAb recognize B cell membrane lgM.  FACS distribution histograms 
with logarithmic amplification for both an mlgM-positive lymphoblastoid cell line (Dau) and 
an mlgM-negative chronic lymphocytic leukemia (Ege) are shown. Cells were incubated with 
1,000  #g/ml  of ultracentrifuged  mAb  followed  by  a  TRITC-F(ab')2  goat  anti-mouse  Ig 
reagent. The binding of each mAb (--) is compared with the binding of an appropriate control 
Ab (- -  -):  MOPC-245  is the lgG1  mouse isotype control, LPC-I  is the lgG2a control, and 
FLOPC-21  is the IgG3 control. The binding of all anti-# mAb to the mlgM-positive cell line 
was >1  log greater than the control Abs. In addition, no significant binding was evident when 
either anti-# or control Abs were tested on an mlgM-negative cell line. 1242  DIVERSITY  OF  HUMAN  B  CELL  RESPONSE  TO  ANTI-IgM  mAb 
TABLE II 
Cross-inhibition RIA to Analyze Epitope Specificity of Anti-IgM Monoclonal Antibodies 
Wells coated  Concentration (#g/ml) of soluble rnAb needed for 50% inhibition of SH-lgM binding to well-bound  mAb* 
with |0 t~g/ml 
of:  HB57  5D7  VIIIEI 1  Mu53  IG6  XG9  P24 
HB57  0.19  115  175  9  43  35  21 
5D7  90  0.64  >1,000  >1,000  23  >1,000  200 
VIIIEI 1  >1,000  >1,000  0.52  >1,000  >1,000  0.28  >1,000 
Mu53  0.79  >1,000  >1,000  2.2  >1,000  >1,000  230 
IG6  >1,000  >1,000  >1,000  >1,000  1.0  >1,090  >1,000 
XG9  >1,000  >1,000  0.75  >l,000  >1,000  0.40  ::-  1,0O0 
* Pvc wells were coated with 10 gg/ml of purified anti-lgM mAb. The ability of various concentra- 
tions of soluble anti-lgM mAb (0.04-25 #g/ml) to inhibit the binding of ~H-IgM (20,501 cpm 
added per well at a 0.5 ~g/ml concentration) was evaluated. All tests were run in duplicate; the 
standard deviation of cpm bound from averaged wells were all <15% of mean value. The cpm of 
~H-IgM bound to mAb-coated wells in the absence of soluble inhibitor were as follows: HB57 
(5,055 cpm), 5D7 (6,469), VIIIEII (9,463), Mu53 (8,253), 1G6 (9,611), XG9 (9,058), and P24 
(867). 
epitope on human  IgM as shown by the fact that no other mAb was capable of 
competing with it in a reciprocal fashion. (b) mAb VIIIE11  and  XG9 bound to 
the  same  or very similar  determinant  since  they strongly competed with  each 
other. This epitope is probably distinct from that recognized by all other mAb 
since no other mAb competed reciprocally. (c) mAb 5D7 presumably binds to a 
unique epitope since it competed only minimally with  HB57 and was inhibited 
only by 1G6, in a  nonreciprocal fashion. (d) mAb HB57 and  Mu53 could have 
specificity for the same or very neighboring site, as they were able to reciprocally 
compete at  low  concentrations.  However,  unlike  mAb  Mu53,  the  binding  of 
HB57 to 3H-IgM could be inhibited to some degree by all the mAb. (e) P24 and 
HB57  appear  to  recognize  the  same  or  very  proximate  epitopes,  since  they 
yielded  identical  patterns  of inhibition  when  used  to  compete  with  all  other 
insolubilized mAb. 
Results  obtained from inhibition assays in which  P24  mAb was insolubilized 
on wells are not included in Table II because the amount of aH-IgM bound to 
such wells was too low to allow reliable inhibition curves to be made. This could 
reflect either a  low affinity of P24 mAb for IgM or a  diminution in its binding 
capacity when the mAb is immobilized onto PVC wells.  It should be noted that 
soluble  P24  mAb  was  very effective at  binding  to  IgM-coated  wells  at  mAb 
concentrations as low as 2.5 ng/ml (data not shown). 
Differential  Ability  of Anti-Igm  mab  to  Induce  Proliferation  of Human  Spleno- 
cytes.  Fig. 2 illustrates the results from three experiments demonstrating differ- 
ences  in  the  ability  of  the  anti-IgM  mAb  to  induce  human  splenic  B  cell 
proliferation in the presence of T  cell supernatant.  Over a  dose range of 0.5- 
1000  t~g/ml,  mAb  HB57  always  induced  the  greatest  proliferation  response. 
While mAb 5D7  induced a  considerably lower degree of stimulation,  it gave a 
similarly shaped dose response profile to that of mAb HB57. With both, a  long 
plateau  of maximal  stimulation  was observed using concentrations of 1,000  to 
nearly 20/~g/ml; mAb concentrations as low as 2 #g/ml resulted in proliferation 
significantly above background. 
The concentration response profiles of mAb Mu53 and VIIIEI 1 were similar w 
+1 
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FIGURE 2.  Individual  anti-lgM mAb vary in ability to induce human splenic B cell prolifer- 
ation.  T  cell-depleted human splenocytes  from two separate  donors (experiments  A and B, 
donor 1  ; experiment C, donor 2) were cultured with various concentrations of purified anti-# 
mAb in  the  presence of 30%  T  cell supernatant.  The proliferative  response  observed in 
control  cultures  with  the  murine  myeloma  MOPC-245  is  also  illustrated.  The  data  are 
expressed  as ~ cpm +  SEM from triplicate  cultures.  Maximal B cell stimulation  was always 
obtained with mAb HB57 and 5D7 (HB57 > 5D7). mAb VIIIEI 1 and Mu53 induced a lower 
level of proliferation that was only manifest at high mAb concentrations.  1G6, XG9, and P24 
mAb usually induced an inhibition  of background proliferation,  indicated  by the solid hori- 
zontal line. 
to  one  another  but  distinct  from  those  of  HB57  and  5D7.  A  much  greater 
concentration  (>100  ~g/ml)  of these  mAb  was  needed  to  induce  a  substantial 
degree of [3H]thymidine uptake.  Furthermore,  the maximal  level of stimulation 
obtained was always much lower than with  HB57 or 5D7 mAbs. Concentrations 
of Mu53  and  VIIIE11  _1,000  #g/ml  did  not  produce  a  definable  plateau  in 
stilnulation. 
In  contrast,  mAb  1G6,  XG9,  and  P24  did  not  induce  stimulation  at  any 
concentration tested in five of six experiments.  In one experiment,  1G6 induced 
proliferation  comparable to that of Mu53.  mAb  XG9 and P24 always inhibited 
background  proliferation.  In  addition,  no  significant  proliferation  over  back- 
ground  was  ever  obtained  with  the  irrelevant  murine  3,1  Ab,  MOPC-245,  at 
concentrations  ~i,000  ~g/ml. 
When experiments were performed  using uhracentrifuged  mAb preparations, 
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noncentrifuged preparations, suggesting that Ab aggregation was not a contrib- 
uting  factor to the  differential responses  observed.  As  demonstrated  in  Table 
III, cultures containing optimal stimulatory doses of ultracentrifuged anti-/~ mAb 
HB57, 5D7,  VIIIE1 1, and  Mu53 were inhibited to background or below back- 
ground  levels  of proliferation  when  500  izg/ml  soluble  pentameric  IgM  was 
added. This suggests that mAb-induced proliferation depends upon the anti-t~- 
ligand interaction and not on a contaminating mitogenic moiety. 
Marked  Augmentation  of  B  Cell  Proliferation  with  Certain  Combinations  of 
mAbs.  Fig. 3 illustrates that a  1 : 1 mixture of the two individually nonstimulatory 
mAb 1G6 and XG9 resulted in a marked enhancement orB cell activation. While 
the individual mAb did not induce >1,209  +  462 cpm of [SH]thymidine incor- 
poration (Acpm +__ SE diff) at any dose tested, the combined mAb (250/xg/ml of 
each) induced 74,391  +  4399 cpm. This level of stimulation was comparable to 
that  elicited  by the  most  stimulatory  individual  mAb,  HB57.  However,  while 
maximal stimulation induced by mAb HB57 was achieved at 20 t~g/ml, maximal 
stimulation induced by the 1:1  1G6-XG9 mAb mixture required >500 ~g/ml of 
total Ab. 
One-to-one mixtures of each of the anti-IgM  mAb, in every paired combina- 
tion, were tested for their mitogenicity. Mixtures of two mAb that induced more 
than  twice the  level of [3H]thymidine incorporation obtained with either mAb 
alone were considered to exhibit the phenomenon of synergy. By this criterion, 
only those mixtures that  included mAb  1G6 and in some instances  mAb XG9 
exhibited synergy. Most other combinations of mAb showed an additive response 
(data not shown). 
The ability of 1G6 and  XG9  mAb to induce synergy in B  cell stimulation  is 
illustrated  in  Fig.  4,  which  shows  that:  (a)  mAb  1G6  markedly  enhanced  the 
proliferation induced by mAb XG9, 5D7, and VIIIE1 1 but induced a  minimal 
degree of enhancement with HB57 and Mu53 and none at all with P24. (b) mAb 
XG9  exhibited synergy with  1G6,  5D7,  and  Mu53,  but  did  not  manifest this 
phenomenon with HB57, VIIIE1 1, or P24. (c) When cultured with mAb Mu53, 
1  G6 and XG9 induced equivalent levels of [SH]thymidine incorporation. In all 
other cases, the combination of a given mAb with  1  G6 always induced a greater 
TABLE III 
Ability of Soluble Human IgM to Inhibit B Cell Proliferation Elicited 
by Ultracentrifuged mAb Preparations 
mAb (ug/ml) 
~" cpm (_+SEM) 
Without inhibitor  Witb IgM inhibitor 
HB57 (125)  67,908 (I ,198)  4,196 (447) 
5D7 (125)  34,754 (2,166)  2,174 (185) 
VIIlE11 (500)  7,471 (962)  2,116 (322) 
Mu53 (500)  7,763 (739)  1,772 (34) 
Media  2,399 (199)  2,258 (75) 
Purified splenic B cells were cultured with HB57, 5D7, VIIIE11, or Mu53 
anti-lgM mAb at the indicated concentrations. All mAb were ultracentri- 
fuged at 108,000 g for 80 min. The top one-third of each was used for 
culture. 500 ltg/ml human IgM was used as inhibitor. 80 
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FIGURE 3.  Synergy in B cell proliferation  when anti-IgM mAb 1G6 and XG9 were cocul- 
tured.  T  cell-depleted  splenic lymphocytes were cultured  with 1G6 mAb (0) or XG9 mAb 
(©) or 1:1 mixtures of the two (I) at various mAb concentrations,  in the presence of 30% T 
cell supernatant.  The mAb concentrations  indicated  reflect  the total  Ab concentration  in 
culture.  Acpm -4- SE diff of culture  triplicates are shown based upon 3,124 +-- 225 (~ cpm --- 
SEM) background [3H]thymidine incorporation. Significant augmentation of B cell stimulation 
was observed when as little as 10 #g/ml of each mAb were cultured together.  No significant 
stimulation  over  background  was  found  when  either  1G6  or  XG9  mAb  were  cultured 
separately at doses up to 500 #g/mt. 
degree of proliferation  than  the  combination  of the  given mAb with  XG9.  (d) 
The  inability  of  XG9  to  induce  synergy  when  cocultured  with  VIIIEll  is 
consistent  with  their  apparent  recognition  of  the  same  epitope  on  the  IgM 
molecule (see Table II). However, these two mAb consistently induced different 
levels of proliferation  when  cultured  with other anti-# mAb.  For example, the 
coculture of XG9 with 5D7 (at 100 #g/ml total Ab) elicited 54,534 +  2,244 cpm 
of [~H]thymidine uptake (XG9 alone, -1,433  +  264; 5D7 alone, 20,955  _+ 857), 
whereas the mixture of 5D7 and VIIIE11 elicited 34,438  +  4,610 cpm of [3H]- 
thymidine incorporation (VIIIE11 alone, 2,393 _-!- 1,032). (e) The lack of synergy 
observed in mixtures containing either  1G6 or XG9 together with P24 does not 
appear to be due  to the delivery of a  negative signal by P24.  The proliferation 
obtained  when  P24  was cocultured  with  individually  mitogenic anti-IgM  mAb 
was not any lower than  that obtained  when  these  latter  mAb were used singly 
(data not shown). 
Absence  of Synergy  Between  1G6 Anti-IgM mAb and mAb Directed  to Non-IgM B 
Cell  Membrane  Molecules.  The  possibility  was  explored  that  the  synergy  ex- 
hibited by mAb 1 G6 could also be obtained by incubation with mAb directed to 
non-IgM molecules on the B cell surface. The data in Table IV show that mAb 
specific to both IgD (CBDA-4E5) and Ia (22c6,  SG171) did not induce prolifer- 
ation and  that,  when these mAb were cultured  with  1 G6 mAb, stimulation  was 
not enhanced.  However, in  the control, a  significant degree of enhancement in 
B cell stimulation was achieved when mAb 1G6 was cocultured with Mu53 anti- 
#  mAb.  When  cultured  separately at  this  concentration,  both  Mu53  and  1G6 
induced no significant degree of proliferation over background. 1246  DIVERS]TY  OF  HUMAN  B  CELL  RESPONSE  TO  ANTI-lgM  mAb 
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FIGURE 4.  Synergy in B cell stimulation when anti-lgM mAb 1G6 or XG9 are cultured with 
other anti-lgM mAb.  Human splenic B cells in medium containing 3])% T  cell supernatant 
were cultured with 250 t~g/ml of mAb A and/or 250 #g/ml of mAb B. The data are expressed 
as Acpm + SE diff. Background stimulation was 3,293 __+ 236 (~ cpm + SEM). Both 1G6 and 
XG9 mAb did not elicit any significant amount of [SH]thymidine uptake in cultured cells when 
used individually; however, when mixed together, or when mixed with 5D7 or Mu53 mAb, 
both induced synergistic responses (see text). In addition, when 1  G6 mAb was cocultured with 
VIIIE11, a marked synergy in the level of [3H]thymidine incorporation was observed. Neither 
1  G6 nor XG9 mAh elicited proliferation when mixed with mAb P24. The inhibition  of HB57- 
induced proliferation obtained when  XG9  was cocultured with  HB57  was reproducible in 
three experiments. 
Comparison of the Effect  of T  Cell Supernatant  Upon Proliferation  Induced  by 
Individual Anti-IgM mAb or mAb Mixtures.  In the absence of T  cell supernatant, 
the B  cell proliferation induced by mAb  HB57  was  markedly reduced.  Never- 
theless, a  ~cpm of 2,597 +  269 was obtained with as little as 4  ug/mi mAb (Fig. 
5) and plateau levels (Acpm,  10,451  +  2,291) of stimulation were reached with 
>20  #g/ml,  the  same  concentration of  HB57  that  gave  plateau  levels  in  the 
presence of T  cell supernatant (Fig.  2).  The  proliferation induced by all other 
individually mitogenic mAb was also substantially reduced in the absence of T RUDICH,  WINCHESTER,  AND  MONGINI  1247 
TABLE  IV 
Inability of 1G6 Anti-IgM mAb to Synergize with mAb Directed to Other B Cell Membrane 
Molecules 
Acpm (SE dill) 
mAb A  mAb B 
None  IG6  Mu53  4E5 Anti-lgD  22c6  Anti-DR  SG157 Anti-DR 
None  --  -1,507 (552)  -67 (696)  -446 (620)  -2,287 (610)  -801 (582) 
IG6  -1,507 (552)  -748 (591)  8,302 (929)  -1,064 (549)  183 (597)  -1,200 (566) 
Purified B cells were cultured with 50 ,~g/ml of purified mAb A and/or mAb B in medium containing 30% T  cell supernatant.  Acpm 
represents the cpm in mAb-containing cultures above that in cultures with medium alone (3,864  + 539 cpm). 
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FIGURE 5.  Comparison of B  cell proliferation induced by single anti-lgM mAb or mAb 
mixtures in the presence and absence of T  cell supernatant. T  cell-depleted splenic lympho- 
cytes were cultured with the indicated concentrations of individual anti-IgM mAb or 1  : 1 mAb 
mixtures in the presence (closed symbols) or absence (open symbols) of 30% T cell supernatant. 
The data are expressed as Acpm + SE diff. Background proliferation with T cell supernatant 
was 3,293  +  236  (~ cpm  -+ SEM).  In the absence of T  cell supernatant,  the proliferation 
induced by each individual mAb was either markedly reduced or not detectable. However, 
when mAb mixtures were tested, a highly significant degree of proliferation was obtained in 
the absence of an exogenous T  cell factor source. In some instances (mAb  IG6 +  5D7 and 
1G6 + XG9), the level of stimulation observed in the absence oft cell supernatant approached 
that obtained for the same cultures in the presence of supernatant. 
cell  supernatant;  in  fact,  low  levels  of stimulation  (Acpm,  1,000-2,500)  were 
observed only in three of seven experiments  in which B  cells were cultured with 
maximal concentrations of 5D7  or Mu53  mAb. 
Fig. 5  also illustrates that,  in  contrast to individual mAb,  certain  mixtures  of 
anti-IgM mAb induced a  significant degree of B  cell proliferation in the absence 
of exogenous T  cell supernatant. Moreover, the level of proliferation approached 
that for the same cultures containing the added  T  cell factor source. 
The ability ofT  cell supernatants to enhance the proliferation ofB lymphocytes 
cultured  with  various concentrations  of individual or  1:1  mixtures  of anti-IgM 
mAb  is evaluated in  Table  V.  The  data demonstrate  that:  (a) the proliferation 1248  DIVERSITY OF  HUMAN  B  CELL  RESPONSE  TO  ANTI-IgM  mAb 
TABLE  V 
Comparison of the Degree of T Cell Supernatant Dependence Exhibited in B Cell Cultures 
Stimulated by High and Low Concentrations of Mitogenic Anti-IgM mAb 
Anti-lgM mAb 
Index of enhancement by T cell supernatant* with total Ab 
concentration at: 
500 ttg/ml  20 #g/rnl 
Exp. A  Exp. B  Exp. C  Exp. A  Exp. B  Exp. C 
HB57  11.12  5.32 
5D7  --*  27.10 
VIIIE11  --  -- 
Mu53  13.11  -- 
1G6 + XG9  2.39  2.04 
+ HB57  1.78  1.40 
+ 5D7  1.27  1.62 
+ VIIIE11  3.29  2.83 
+ Mu53  7.19  3.03 
XG9 + HB57  5.47  4.73 
+ 5D7  7.73  8.35 
+ Mu53  7.79  5.42 
HB57 + 5D7  8.74  5.55 
+ VIIIE11  12.23  5.50 
+ Mu53  4.32  4.24 
5D7 + VIIIE11  13.23  8.32 
+  Mu53  11.35  8.45 
VIIIEI 1 + Mu53  10.99  4.15 
11.09  7.25  4.77  10.96 
29.13  --  --  16.63 
4.67  --  --  -- 
11.64  --  --  2.65 
7.50  5.53 
15.95  15.11 
10.45  5.90 
8.10  6.93 
17.29  11.23 
9.92  6.26 
9.21  7.17 
16.68  8.41 
24.80  8.78 
--  24.37 
6.17 
* Index of T  cell supernatant (T-supt)  enhancement was calculated  by dividing the Acpm in anti- 
IgM-stimulated cultures containing T-supt by the Acpm in anti-lgM-stimulated cultures without 
T-supt. 
* Index was not calculated  because  the denominator (Acpm in cultures without T-supt)  was too low 
to give a reliable  index.  Index values were only calculated  when both the Acpm observed in anti- 
IgM-stimulated cultures containing T-supt and the Acpm observed in stimulated  cultures without 
T-supt were each >2.5 standard deviations of the ~ cpm in the respective control cultures.  Control 
cultures without T-supt exhibited ~ 4- SD values of 2,049  4- 370, 2,177  4- 355, and 759 4- 122 cpm 
in Exps. A, B, and C, respectively.  Control cultures containing 30% T-supt exhibited 3,293  + 471, 
3,124  4- 225, and 1,950 4- 170 cpm in Exp. A, B, and C, respectively. 
induced by each individual anti-IgM mAb was markedly enhanced in the presence 
of T  cell supernatant,  as  indicated by  the  large index values (see  Materials and 
Methods).  (b) Cultures stimulated with the low-dose stimulatory mAb (HB57 or 
5D7) showed no significant difference in T  cell supernatant dependence  at high 
or  low  mAb  concentrations.  Even  when  mAb  doses  suboptimal  for  maximal 
proliferation were tested (data  not shown),  T  celt supernatants  did not enhance 
stimulation  to  any  greater  degree  than  when  optimal  concentrations  of mAb 
were  used.  (c)  In  contrast,  cultures  stimulated  with  mAb  mixtures  containing 
1 G6 generally exhibited a  high degree of T  cell supernatant  independence (i.e., 
low index  values),  manifested at  high  mAb  doses  but diminishing at  low doses. 
(d)  Cultures  stimulated  by  mAb  mixtures  without  1G6  showed  a  much  less RUDICH,  WINCHESTER,  AND  MONG1NI  1249 
pronounced, in many cases negligible, difference in T  cell supernatant depend- 
ence at high and low mAb concentrations. 
Comparison of T Cell Supernatant-replacing  Ability of mAb 1G6 and XG9.  Fig. 
6 illustrates that the synergy obtained by coculturing mAb 1  G6 with each of the 
anti-u mAb  in the absence of T  cell supernatant  was at least equivalent to the 
synergy obtained when the non-lG6 mAb were cocultured with T  cell superna- 
tant alone. Only with mAb Mu53 did the T  cell factor source function better as 
a  costimulator  than  1G6.  Compared  with  1G6,  XG9  was  considerably  less 
effective as a costimulator than the T  cell supernatant. 
We considered the possibility that DEAE-purified 1  G6 was contaminated with 
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FIGURE  6.  Comparison  of T  cell  supernatant-replacing  ability  of mAbs  IG6  and  XG9. 
Cultures  of  T  cell-depleted  splenic  lymphocytes containing  250  ug/ml  of mAb  A  were 
supplemented with 250 #g/ml of mAb B (IG6 or XG9) or 30%  T  cell supernatant (T-supt). 
The data are expressed as Acpm +  SE diff of triplicate cultures.  Background cpm in control 
cultures was 3,124  +  225 (,~ cpm ±  SEM).  In nearly all cultures, mAb 1G6 functions as well, 
if not better,  than T  cell supernatant  in augmenting B  cell stimulation;  the only exception 
being mAb Mu53-stimulated cultures.  In contrast, mAb XG9 was unable to augment B cell 
proliferation when used as a costimulator in the absence of T  cell supernatant. 1250  DIVERSITY  OF  HUMAN  B  CELL  RESPONSE  TO  ANTI-lgM  mAb 
a B cell growth factor (BCGF)-like factor. Further purification of 1  G6 on protein 
A Sepharose or on Sepharose coupled with purified goat anti-mouse Ig antibody, 
revealed that  the synergistic properties were associated with the  bound mouse 
IgG antibody (data not shown). 
Discussion 
One principal  finding  in  this  study was that  various anti-IgM  mAb differed 
significantly in their ability to induce proliferation of human  splenic B lympho- 
cytes. HB57 and  5D7  produced high  plateau  levels of stimulation  at very low 
concentrations.  These  two mAb  induced  significant  proliferation  above back- 
ground with concentrations as low as 2 ~g/ml.  VIIIE11  and Mu53, in contrast, 
induced a lesser degree of proliferation and only at high concentrations.  Finally, 
anti-IgM mAb 1G6, P24, and XG9 did not produce significant proliferation, but 
usually caused an inhibition  of background [3H]thymidine incorporation over a 
broad dose range. 
These  findings,  together  with  the  results of recent reports  (17,  21,  38-40), 
bear importantly  on past studies  (1-16,  18-20,  22) of the  effect of polyclonal 
anti-IgM Ab on B cells. The Ab in anti-Ig sera are a  mixture of distinct species 
that are likely drawn  from the different prototype mAb described above. As a 
result,  the  degree  of proliferation  elicited  and  the  dose required  for  optimal 
stimulation  by  polyclonal  Ab  will  to  some  degree  reflect  the  nature  of the 
individual Ab comprising such polyclonal preparations. 
How is it that different mAb, each with specificity for the same molecule, are 
able to elicit such different  degrees  of stimulation?  A  number  of factors  may 
influence  the  ability  of distinct  anti-IgM  mAb  to  induce  proliferation  of  B 
lymphocytes. The  avidity of an  mAb  for epitopes on  membrane  Ig is a  likely 
factor. In this regard, Hamano and Asofsky have recently described an association 
between the affinity of two rat mAb to mouse IgM and  their ability to induce 
differentiation of a routine B cell line (41). 
The  ability  to  induce  B  cell  proliferation  could  also  be  influenced  by  the 
epitope specificity of the mAb. This association could reflect the mechanism by 
which B cells receive stimulatory signals. There are at least two explanations of 
how anti-lg  Ab trigger  B cell proliferation,  which are not necessarily mutually 
exclusive. Binding to certain epitopes may cause a conformational change in the 
mIgM  molecule  that  aids  in  the  initiation  of intracellular  signals  required  for 
proliferation.  Alternatively,  signals  may arise  from  the  aggregation  of mIgM 
molecules (43).  With  regard  to this  latter  mechanism,  it is likely that  an  mAb 
which recognizes an  epitope multiply expressed on an  mIgM  molecule will  be 
more efficient at crosslinking  mIgM  molecules than  an  mAb that  recognizes a 
singly expressed epitope. 
Many of the anti-IgM mAb found to exhibit distinct patterns of stimulation in 
this study also recognize unique epitopes on IgM. These results are compatible 
with  the  possibility  that  epitope  specificity  influences  mitogenic  potential.  In 
addition, Julius et al.  (39), as well as Zitron  and  Clevinger (38), have reported 
that  two mAb pairs,  directed  to  epitopes on  different  domains  of the  murine 
lgM  and  lgD  molecule,  respectively,  vary  in  their  ability  to  induce  B  cell 
proliferation.  The binding to a particularly sensitive, domain-associated epitope RUDICH, WINCHESTER, AND MONGINI  1251 
may be important  in signaling since the recent data of Leptin (40) indicate that 
two soluble rat anti-murine  IgM mAb which share domain specificity and isotype 
with the mitogenic mAb described by Julius et al. (39) both fail to induce murine 
B cell proliferation. 
The effects of Ab binding to Fc receptors has been shown to influence B cell 
activation by anti-Ig Ab (10,  19-21).  However, it is unlikely that an Fc region- 
mediated mechanism is responsible for all differences in the mitogenic character 
of the  individual  anti-#  mAb  in  this  study,  since  five of those  that  displayed 
functional  differences were of the  same  3"1  isotype. The  possibility cannot  be 
excluded  that  the  difference  in  stimulatory  capacity  between  mAb  XG9  (3"1 
murine isotype) and VIIIE11 (3"3 murine isotype) could be due to Fc differences, 
since the available evidence indicates that they both bind to the same epitope. 
Of particular  interest is the finding that the individually nonstimulatory mAb 
1G6 and XG9 give a  very strong mitogenic response when incubated together. 
Moreover, synergy was observed when either  1G6 or XG9 was cocultured with 
all but two of the anti-IgM mAb. This was apparent not only at high concentra- 
tions (250 ug/ml) of each mAb, but also at concentrations  as low as  10 #g/ml. 
Indeed,  the  only  instance  in  which  1G6  did  not  markedly  augment  existing 
stimulation was in co-incubation with HB57 in the presence oft  cell superuatant. 
This could reflect the fact that in such cultures HB57 mAb alone elicits a near- 
maximal B cell response. This possibility is strengthened by the observation that, 
in  the  absence  of T  cell  supernatant,  1G6  strikingly  enhances  the  maximal 
stimulation  achieved  with  HB57.  It  is  important  to  consider  that  mAb  IG6 
induced synergy in B cell proliferation when combined with other anti-IgM mAb 
but not when combined with mAb to other surface molecules, such as anti-Ia or 
anti-&  However, since a  limited number of anti-Ia and anti-6  mAb were tested, 
the possibility remains that others might display synergy with mAb 1G6. 
At present,  there is no satisfactory interpretation  for the absence of synergy 
between mAb XG9 and  HB57 even in the absence of T  cell supernatant.  One 
reasonable explanation may be that, when combined, they have a reduced ability 
to  induce  positive signals  for  B  cell  proliferation.  This  could also explain  the 
inability of mAb  1G6 and  XG9 to induce B cell proliferation  when either  was 
used in combination with P24. 
At least three possible mechanisms for the synergy demonstrated in cocultures 
of anti-u mAb with mAb  1  G6 (or XG9) can be considered: (a) cyclic complexes 
may form  between mAb  1G6,  mIgM,  and  other anti-~  mAb,  which  lead to a 
greater overall avidity of the ligands for mIgM.  Ehrlich et al. (43) have recently 
described cyclic complexes of mAb that display a higher affinity for antigen than 
the  individual  mAb.  In  addition,  Parham  (44)  has  shown  that  the  binding  of 
certain mAb to a major histocompatibility complex molecule induces conforma- 
tiona] changes that affect the affinity with which other mAb bind to alternative 
epitopes on the  molecule.  (b) The ability of mAb  1G6  to induce synergy may 
simply  reflect  its  unique  ability  to  collaborate  with  other  mAb  in  inducing 
efficient crosslinkage of mIgM molecules and consequent stimulatory micropatch 
formation  (42) on  the  B  cell  membrane.  It  is  unlikely  that  this  mechanism  is 
solely responsible for the observed synergy since other pairs of mAb that bind 
to unique epitopes and  thus should be capable of increasing crosslinkage (e.g., 1252  DIVERSITY  OF  HUMAN  B  CELL  RESPONSE  TO  ANTI-IgM  mAb 
5D7 and VIIIE11 or Mu53 and VIIIE11) do not display synergy when combined. 
(c)  The  exceptional  ability  of  1G6  mAb  to  synergize  may  reflect  its  unique 
capability to induce confonnational changes that enhance the efficiency of signal 
transfer  from mIgM to the B cell interior after binding to mIgM with another 
anti-IgM Ab. 
Studies with anti-IgM Ab from polyclonal antisera (45, 46) have shown that B 
cell  proliferation  elicited  by low Ab concentrations  is  dependent  upon  T  cell 
factors, while proliferation  elicited by high  concentrations of Ab is relatively T 
cell  independent.  In  contrast,  our experiments  with  individual  anti-IgM  mAb 
indicate that,  irrespective of the dose of Ab, the proliferation  induced by each 
individual mAb is significantly enhanced by the presence ofa T  cell factor source. 
Of particular  interest is our finding that  the cocultivation of mAb  1G6 with 
other anti-IgM mAb circumvents the need for a second signal to be delivered to 
B cells by T  cell supernatant.  We did not examine whether these mAb mixtures, 
at high  concentrations,  recruit  the proliferation  of a  B cell subpopulation  that 
does not require second signals from exogenous factors, or whether signals from 
these mixtures abrogate  the  need for additional  signaling  to one responsive B 
cell subpopulation.  In  addition,  although  the data clearly show that  mAb  1G6 
has specificity for human  IgM, they do not rule out the possibility that  1  G6 may 
crossreact with the BCGF receptor on human B lymphocytes and thereby mimic 
the effects of BCGF. Given that  B cells are  capable of secreting B cell growth 
factor when infected with Epstein-Barr virus (47), it is also conceivable that the 
signals  delivered  by  mAb  1G6,  in  combination  with  another  anti-IgM  mAb, 
induce B cells to secrete their own endogenous growth factor that eliminates the 
need for exogenous factor. These possible mechanisms for the unique properties 
of mAb 1  G6 remain to be investigated. 
Summary 
Seven murine monoclonal antibodies (mAb) with different binding character- 
istics for human  IgM varied markedly in their ability to induce proliferation  of 
T  cell-depleted human  splenocytes. Two mAb (HB57 and 5D7) that bound to 
distinct epitopes on IgM were highly effective initiators of B cell proliferation at 
very  low  concentrations,  in  the  presence  of a  T  cell  factor  source.  In  the 
absence of T  cell supernatant,  both HB57 and 5D7 mAbs produced a markedly 
reduced  degree  of stimulation  at  all  concentrations.  Two additional  anti-IgM 
mAb (VIIIE11  and Mu53) were distinctive in that, even at high concentrations, 
only limited proliferation was observed compared with the first group of mAb. 
This proliferation depended on the presence of T  cell supernatant.  Competitive- 
binding  studies  revealed  that  the  epitope  recognized  by mAb  Mu53  may  be 
identical or very proximate to that recognized by HB57. Three other mAb (1G6, 
XG9, and P24) induced little or no proliferation.  1G6 bound to a unique epitope 
on the IgM molecule, whereas XG9 shared a  determinant  with VlIIE11  mAb. 
Regulatory influences of Fc receptor binding cannot account for all the diversity 
in proliferation observed with the individual anti-IgM mAb. 
Markedly augmented  proliferation  was obtained when  B cells were cultured 
with certain combinations of anti-IgM mAb in the presence of exogenous T  cell 
supernatant.  The proliferation  induced in the absence of T  cell supernatant  by RUDICH,  WINCHESTER,  AND  MONGINI  1253 
high  concentrations  of mAb mixtures  that  included  1G6  approached  that  ob- 
served  for the  same mixtures  in  the  presence of T  cell  supernatant.  The  data 
suggest  that  certain  signals  delivered  through  membrane  IgM  can  bypass the 
need for T  cell supernatant in the activation of human B lymphocytes. 
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